Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 27Cisplatin 17Nivolumab 14Cyclophosphamide 14Carboplatin 13Radiation 12Paclitaxel 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Cytarabine 9Vincristine 8Magnetic Resonance Spectroscopy 8Docetaxel 8Bevacizumab 8Radiosurgery 7Leucovorin 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Pemetrexed 6Irinotecan 6Injections 6Gemcitabine 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × budigalimab × 30 days × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡